Future randomized controlled trials with larger populations, longer follow-up periods, and comprehensive nutritional and molecular assessments are needed to confirm these findings, explore underlying mechanisms, and assess the long-term impact of dietary strategies on the ATX–LPA axis and MASLD progression. The gene discussed is ENPP2; the disease is metabolic dysfunction-associated steatotic liver disease.